A phase III trial of CA-002 for the treatment of peanut allergies
Latest Information Update: 24 Jan 2024
At a glance
- Drugs CA 002 (Primary)
- Indications Peanut hypersensitivity
- Focus Adverse reactions; Registrational; Therapeutic Use
Most Recent Events
- 24 Jan 2024 New trial record